Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.

Next Previous
X
Search
Trial Profile

A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB-002T (Primary) ; Capecitabine; Carboplatin; Cisplatin; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Biliary cancer; Bladder cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Lung cancer; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Huabo Biopharm

    • Most Recent Events

    • 06 Jun 2023 Results (n= 68, data cut off date- 20 Dec 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 22 Mar 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top